FDA panel backs Heplisav-B, requests details for postmarketing study

FDA's Vaccines and Related Biological Products Advisory Committee voted 12 to 1, with 3 abstentions, that available safety data support the use of HBV vaccine Heplisav-B from Dynavax Technologies

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE